Quantification of Peripheral Blood iNKTs After Allogeneic Stem Cell Transplantation

Starting soon

Conditions studied: Allogeneic HSCT, Posttransplant Complications, GvHD, Relapse, Acute Myeloid Leukemia

In brief

The transplantation of allogeneic haematopoietic stem cells (HSCs) can lead to serious complications after transplantation, such as graft-versus-host disease (GvHD), infections and relapse due to immunosuppression. Invariant NKT cells (iNKT cells) play a pivotal role in modulating the immune response and have been demonstrated to be instrumental in the pathogenesis of GvHD, cytomegalovirus (CMV) infection, and relapse. Their levels are associated with the development of these complications. This multicentre study aims to test the feasibility of standardising iNKT cell monitoring and to investigate the association between iNKT cell levels and post-transplant complications.

Key facts

Study ID

NCT07570407

Run by

University Hospital Pilsen

People needed

75

Starts

2026-05-01

Expected to finish

2029-01-31

Last updated by the study team

2026-05-06

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis: AML (exlusion of secondary disease)
• Disease status at time of HSCT: complete remission
• Karnofsky performance status: ≥80%
• Source of HSC: PBSC

You may not qualify if…

• Prior transplant
• Uncontrolled Malignancy

Where it is running

• University Hospital Pilsen — Pilsen, Czechia, Czechia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.